Robbins LLP Informs Investors About Ultragenyx Pharmaceutical Class Action Lawsuit
In a significant legal development, Robbins LLP has alerted investors about a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The lawsuit is pertinent to all stockholders who acquired shares between August 3, 2023, and December 26, 2025. Ultragenyx, a biopharmaceutical company focusing on rare genetic disorders, is under scrutiny for potential misleading communications regarding its clinical study results.
The lawsuit revolves around the Phase III Orbit and Cosmic studies, which evaluated setrusumab (UX 143) in patients suffering from Osteogenesis Imperfecta (OI). The plaintiffs assert that during the class period, Ultragenyx provided overly optimistic statements about the expected benefits of setrusumab, leading investors to believe in the drug's efficacy and the integrity of the study designs.
According to the allegations, Ultragenyx’s statements suggested confidence in setrusumab's ability to reduce the annualized fracture rate in patients with OI. However, the complaint reveals a contrasting narrative, claiming that while setrusumab may enhance bone density, it does not necessarily correlate with a reduction in fractures. This discrepancy painted a misleading picture regarding the true potential of the drug and concealed significant drawbacks in the study protocols.
On December 29, 2025, Ultragenyx announced that neither the Phase III Orbit nor Cosmic studies had achieved statistical significance concerning their primary endpoints. This revelation led to a drastic fall in the company’s stock price, dropping approximately 42.32% in just one day, from $34.19 to $19.72 per share. Such drastic changes have prompted Robbins LLP to act on behalf of affected investors.
Investors who purchased Ultragenyx shares during the specified time frame may be eligible to participate in this class action lawsuit. Those interested in becoming lead plaintiffs are advised to contact Robbins LLP, as they will represent fellow shareholders in the ongoing litigation. However, participation is not mandated for recovery; investors may also choose to remain as absent class members if they wish.
Robbins LLP, a recognized leader in shareholder rights litigation, has been dedicated to protecting the interests of investors since 2002. The firm emphasizes a commitment to recovering losses, enhancing corporate governance, and holding company executives accountable for any misconduct. Clients incur no fees unless they secure compensation through the case, as all representation operates on a contingency fee basis.
To remain updated on developments concerning this class action or to be notified about any future settlements related to Ultragenyx Pharmaceutical Inc., stakeholders are encouraged to subscribe to Stock Watch. This service alerts investors when executives engage in any wrongdoing, ensuring that they stay informed about their investments.
The Ultragenyx case serves as a reminder of the importance of transparency and accountability in the pharmaceutical industry. Investors should remain vigilant and proactive in safeguarding their rights and interests, particularly in light of the potentially misleading statements of major pharmaceutical brands.
For more information regarding your eligibility in this class action, or to speak directly with an attorney at Robbins LLP, contact their office without delay, ensuring that your rights as an investor are protected.
Background
The lawsuit revolves around the Phase III Orbit and Cosmic studies, which evaluated setrusumab (UX 143) in patients suffering from Osteogenesis Imperfecta (OI). The plaintiffs assert that during the class period, Ultragenyx provided overly optimistic statements about the expected benefits of setrusumab, leading investors to believe in the drug's efficacy and the integrity of the study designs.
According to the allegations, Ultragenyx’s statements suggested confidence in setrusumab's ability to reduce the annualized fracture rate in patients with OI. However, the complaint reveals a contrasting narrative, claiming that while setrusumab may enhance bone density, it does not necessarily correlate with a reduction in fractures. This discrepancy painted a misleading picture regarding the true potential of the drug and concealed significant drawbacks in the study protocols.
Developments
On December 29, 2025, Ultragenyx announced that neither the Phase III Orbit nor Cosmic studies had achieved statistical significance concerning their primary endpoints. This revelation led to a drastic fall in the company’s stock price, dropping approximately 42.32% in just one day, from $34.19 to $19.72 per share. Such drastic changes have prompted Robbins LLP to act on behalf of affected investors.
What Investors Should Know
Investors who purchased Ultragenyx shares during the specified time frame may be eligible to participate in this class action lawsuit. Those interested in becoming lead plaintiffs are advised to contact Robbins LLP, as they will represent fellow shareholders in the ongoing litigation. However, participation is not mandated for recovery; investors may also choose to remain as absent class members if they wish.
Why Choose Robbins LLP?
Robbins LLP, a recognized leader in shareholder rights litigation, has been dedicated to protecting the interests of investors since 2002. The firm emphasizes a commitment to recovering losses, enhancing corporate governance, and holding company executives accountable for any misconduct. Clients incur no fees unless they secure compensation through the case, as all representation operates on a contingency fee basis.
Get Informed
To remain updated on developments concerning this class action or to be notified about any future settlements related to Ultragenyx Pharmaceutical Inc., stakeholders are encouraged to subscribe to Stock Watch. This service alerts investors when executives engage in any wrongdoing, ensuring that they stay informed about their investments.
Conclusion
The Ultragenyx case serves as a reminder of the importance of transparency and accountability in the pharmaceutical industry. Investors should remain vigilant and proactive in safeguarding their rights and interests, particularly in light of the potentially misleading statements of major pharmaceutical brands.
For more information regarding your eligibility in this class action, or to speak directly with an attorney at Robbins LLP, contact their office without delay, ensuring that your rights as an investor are protected.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.